Cargando…
Author correction to ‘Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer’ [Acta Pharmaceutica Sinica B 2019; 9(5):1061–1077]
Autores principales: | Mei, Dong, Chen, Binlong, He, Bing, Liu, Haibin, Lin, Zhiqiang, Lin, Jialiang, Zhang, Xiaoyan, Sun, Ning, Zhao, Libo, Wang, Xiaoling, Zhang, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332668/ https://www.ncbi.nlm.nih.gov/pubmed/32642419 http://dx.doi.org/10.1016/j.apsb.2020.03.003 |
Ejemplares similares
-
Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer
por: Mei, Dong, et al.
Publicado: (2019) -
Author correction to ‘Approved HIV reverse transcriptase inhibitors in the past decade’ [Acta Pharmaceutica Sinica B 12 (2022) 1567–1590]
por: Li, Guangdi, et al.
Publicado: (2023) -
Author correction to “Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers” [Acta Pharmaceutica Sinica B 11 (2021) 355–372]
por: Jiang, Tingting, et al.
Publicado: (2022) -
Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11(2021) 1903–1913]
por: Yu, Ziru, et al.
Publicado: (2023) -
Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11 (2021) 1903–1913]
por: Yu, Ziru, et al.
Publicado: (2023)